Inspire Medical Systems (INSP) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 May, 2026Opening remarks and agenda
The meeting was held virtually, welcoming live questions from stockholders and introducing the board and management team members present.
Financial performance review
Achieved $912 million in revenue for 2025, marking 14% year-over-year growth and surpassing 125,000 patients treated.
Approaching the $1 billion revenue milestone, with continued focus on profitability and strong operating margins.
Board and executive committee updates
Welcomed Matt Osberg as Chief Financial Officer and elevated Carlton Weatherby to Chief Strategy and Growth Officer in early 2026.
Board and senior leadership team collaboration highlighted as key to effective oversight and strategic direction.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Inspire Medical Systems
- Q2 2026 revenue fell 7.6% but gross margin rose; guidance and growth investments increased.INSP
Q2 2026 - Inspire V advances clinical outcomes and reimbursement clarity, supporting growth in sleep apnea care.INSP
Wells Fargo 2026 MedTech Innovation Spotlight - Coding and reimbursement headwinds drive near-term revenue decline, but sequential improvement is expected.INSP
Bank of America Global Healthcare Conference 2026 - Q1 revenue rose 1.6% to $204.6M, but net loss widened and guidance was cut on reimbursement headwinds.INSP
Q1 2026 - 2025 saw double-digit revenue growth, board declassification plans, and expanded ESG initiatives.INSP
Proxy filing - Key votes include director elections, auditor ratification, and board structure changes.INSP
Proxy filing - 2026 guidance: $950M–$1.0B revenue, 4%–10% growth, with reimbursement risks.INSP
Q4 2025 - Q2 2024 revenue up 30% to $195.9M, net income $9.8M, guidance and share repurchase raised.INSP
Q2 2024 - Record 2024 revenue and EPS growth set stage for 17–19% sales increase in 2025.INSP
Q4 2024